Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synflorix Immunogenicity in At-Risk Children
NCT01746108Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2013
- Primary completion
- Jun 2015
- Modality
- Split/Subunit Vaccines
- Countries
- 2
01
Overview
Phase 3, open-label trial of 10-valent pneumococcal conjugate vaccine in pneumococcal infection (4 arms), sponsored by GSK. Primary endpoints: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes, Opsonophagocytic Titers Against Vaccine Pneumococcal Serotypes and 1 more. Started Jun 2013; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01746108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746108.